Although the rebate system used to set list prices for insulin products in the U.S. bears all the hallmarks needed for a Racketeer Influenced and Corrupt Organizations (RICO) action, a federal judge ruled that patients lack the standing, at least in the Third Circuit, to bring such actions against drug companies because they don't buy the drugs directly from the manufacturer.